跳至主要内容
临床试验/JPRN-UMIN000011174
JPRN-UMIN000011174已完成2 期

A randomized Phase II study of Carboplatin + Pemetrexed followed by Pemetrexed versus Carboplatin+Pemetrexed followed by Erlotinib in patients with advanced Non-squamous and Non- Small Cell Lung Cancer with EGFR sensitive mutations LOGIK1302- - LOGIK1302

ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 65 人开始时间: 2013年7月11日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
65

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) EGFR mutation T790M positive 2) Active severe comorbidity disease. 3) Interstitial pneumonia or pulmonary fibrosis on chest CT scans. 4) Patients with symptomatic Brain metastases. 5) Active concomitant malignancy. 6) History of grave drug allergic reaction. 7) Pregnant or breast-feeding females. 8) Unstable psychic disorder. 9) Accepted continuous use of steroid. 10) Administration of folic acid and vitamin B12 is not received. 11) Inappropriate patients for this study judged by the physicians.

研究者

发起方
ung Oncology Group in Kyushu, Japan (LOGIK)

相似试验